- Recommendation ID
- TA340/1
- Question
NICE considered that there is an important need for head-to-head comparisons between biological treatments for psoriatic arthritis, particularly in people for whom treatment with tumour necrosis factor (TNF) alpha inhibitors has been unsuccessful.
- Any explanatory notes
(if applicable) None.
Source guidance details
- Comes from guidance
- Ustekinumab for treating active psoriatic arthritis
- Number
- TA340
- Date issued
- June 2015
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |